Splanchnic vein thrombosis associated with myeloproliferative neoplasms

Douglas Tremblay; Adam Winters; Joan D. Beckman; Leonard Naymagon; Rahul Patel; John Mascarenhas; Thomas D. Schiano

doi:10.1016/j.thromres.2022.08.003

Splanchnic vein thrombosis associated with myeloproliferative neoplasms

Douglas Tremblay, Adam Winters, Joan D. Beckman, Leonard Naymagon, Rahul Patel, John Mascarenhas, Thomas D. Schiano

Research output: Contribution to journal › Review article › peer-review

14 Scopus citations

Abstract

Splanchnic vein thrombosis (SVT) in the setting of myeloproliferative neoplasm (MPN) is a unique clinical entity that requires close interdisciplinary coordination for proper diagnosis and management. The pathobiology of MPN-SVT is not fully understood, but recent developments have revealed the central role of endothelial cells. In this multidisciplinary review, we summarize the epidemiology of MPN-SVT and then critically evaluate the pathogenic features of this complication, with a focus on endothelial cell biology. We then discuss diagnostic considerations, including imaging modalities and MPN-specific investigations. Finally, we critically review the evidence supporting clinical management of MPN-SVT, including anticoagulation, interventional radiology procedures, MPN-related therapies, and liver transplantation. We conclude that further studies are needed to improve our understanding of MPN-SVT and the outcomes of patients with this debilitating complication.

Original language	English (US)
Pages (from-to)	8-16
Number of pages	9
Journal	Thrombosis Research
Volume	218
DOIs	https://doi.org/10.1016/j.thromres.2022.08.003
State	Published - Oct 2022

Bibliographical note

Funding Information:
DT receives research clinical research funding from Astellas Pharma and consulting fees from AbbVie and CTI Biopharma. JDB receives research funding from Bayer independent of studies herein. RP receives consultancy fees from Sirtex Medical and is on the advisory boards of Medtronic, Blackswan Medical, and Scientia Inc. and is on the speakers' bureau of Medtronic. JM receives clinical research funding from Incyte, Janssen, CTI Biopharma, PharmaEssentia, Novartis, Roche, Kartos, Promedior Merck and consulting fees from Promedior, Prelude, Galecto, Incyte, Celgene, Kartos, and Geron. The rest of the authors have no financial conflicts of interest to disclose.The authors would like to acknowledge Jill Gregory for the creation of Fig. 1. The authors would like to acknowledge Michael Franklin, MS for assistance in editing the manuscript. J.D.B. is supported in part by Institutional Research Grant #129819-IRG-16-189-58-IRG-114 from the American Cancer Society, OT2 HL15275801 and American Heart Association Career Development Award.

Funding Information:
J.D.B. is supported in part by Institutional Research Grant # 129819-IRG-16-189-58-IRG-114 from the American Cancer Society , OT2 HL15275801 and American Heart Association Career Development Award.

Funding Information:
DT receives research clinical research funding from Astellas Pharma and consulting fees from AbbVie and CTI Biopharma. JDB receives research funding from Bayer independent of studies herein. RP receives consultancy fees from Sirtex Medical and is on the advisory boards of Medtronic, Blackswan Medical, and Scientia Inc. and is on the speakers' bureau of Medtronic. JM receives clinical research funding from Incyte , Janssen , CTI Biopharma , PharmaEssentia , Novartis , Roche , Kartos , Promedior Merck and consulting fees from Promedior, Prelude, Galecto, Incyte, Celgene, Kartos, and Geron. The rest of the authors have no financial conflicts of interest to disclose.

Publisher Copyright:
© 2022 Elsevier Ltd

Keywords

Essential thrombocythemia
Myelofibrosis
Myeloproliferative
Polycythemia vera
Splanchnic vein
Thrombosis

PubMed: MeSH publication types

Journal Article
Review

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Publisher link

10.1016/j.thromres.2022.08.003

Find It

Find It at U of M Libraries

Cite this

@article{2fd18691c5b9491bb94a6851cb949453,

title = "Splanchnic vein thrombosis associated with myeloproliferative neoplasms",

abstract = "Splanchnic vein thrombosis (SVT) in the setting of myeloproliferative neoplasm (MPN) is a unique clinical entity that requires close interdisciplinary coordination for proper diagnosis and management. The pathobiology of MPN-SVT is not fully understood, but recent developments have revealed the central role of endothelial cells. In this multidisciplinary review, we summarize the epidemiology of MPN-SVT and then critically evaluate the pathogenic features of this complication, with a focus on endothelial cell biology. We then discuss diagnostic considerations, including imaging modalities and MPN-specific investigations. Finally, we critically review the evidence supporting clinical management of MPN-SVT, including anticoagulation, interventional radiology procedures, MPN-related therapies, and liver transplantation. We conclude that further studies are needed to improve our understanding of MPN-SVT and the outcomes of patients with this debilitating complication.",

keywords = "Essential thrombocythemia, Myelofibrosis, Myeloproliferative, Polycythemia vera, Splanchnic vein, Thrombosis",

author = "Douglas Tremblay and Adam Winters and Beckman, {Joan D.} and Leonard Naymagon and Rahul Patel and John Mascarenhas and Schiano, {Thomas D.}",

note = "Funding Information: DT receives research clinical research funding from Astellas Pharma and consulting fees from AbbVie and CTI Biopharma. JDB receives research funding from Bayer independent of studies herein. RP receives consultancy fees from Sirtex Medical and is on the advisory boards of Medtronic, Blackswan Medical, and Scientia Inc. and is on the speakers' bureau of Medtronic. JM receives clinical research funding from Incyte, Janssen, CTI Biopharma, PharmaEssentia, Novartis, Roche, Kartos, Promedior Merck and consulting fees from Promedior, Prelude, Galecto, Incyte, Celgene, Kartos, and Geron. The rest of the authors have no financial conflicts of interest to disclose.The authors would like to acknowledge Jill Gregory for the creation of Fig. 1. The authors would like to acknowledge Michael Franklin, MS for assistance in editing the manuscript. J.D.B. is supported in part by Institutional Research Grant #129819-IRG-16-189-58-IRG-114 from the American Cancer Society, OT2 HL15275801 and American Heart Association Career Development Award. Funding Information: J.D.B. is supported in part by Institutional Research Grant # 129819-IRG-16-189-58-IRG-114 from the American Cancer Society , OT2 HL15275801 and American Heart Association Career Development Award. Funding Information: DT receives research clinical research funding from Astellas Pharma and consulting fees from AbbVie and CTI Biopharma. JDB receives research funding from Bayer independent of studies herein. RP receives consultancy fees from Sirtex Medical and is on the advisory boards of Medtronic, Blackswan Medical, and Scientia Inc. and is on the speakers' bureau of Medtronic. JM receives clinical research funding from Incyte , Janssen , CTI Biopharma , PharmaEssentia , Novartis , Roche , Kartos , Promedior Merck and consulting fees from Promedior, Prelude, Galecto, Incyte, Celgene, Kartos, and Geron. The rest of the authors have no financial conflicts of interest to disclose. Publisher Copyright: {\textcopyright} 2022 Elsevier Ltd",

year = "2022",

month = oct,

doi = "10.1016/j.thromres.2022.08.003",

language = "English (US)",

volume = "218",

pages = "8--16",

journal = "Thrombosis Research",

issn = "0049-3848",

publisher = "Elsevier Ltd",

}

TY - JOUR

T1 - Splanchnic vein thrombosis associated with myeloproliferative neoplasms

AU - Tremblay, Douglas

AU - Winters, Adam

AU - Beckman, Joan D.

AU - Naymagon, Leonard

AU - Patel, Rahul

AU - Mascarenhas, John

AU - Schiano, Thomas D.

N1 - Funding Information: DT receives research clinical research funding from Astellas Pharma and consulting fees from AbbVie and CTI Biopharma. JDB receives research funding from Bayer independent of studies herein. RP receives consultancy fees from Sirtex Medical and is on the advisory boards of Medtronic, Blackswan Medical, and Scientia Inc. and is on the speakers' bureau of Medtronic. JM receives clinical research funding from Incyte, Janssen, CTI Biopharma, PharmaEssentia, Novartis, Roche, Kartos, Promedior Merck and consulting fees from Promedior, Prelude, Galecto, Incyte, Celgene, Kartos, and Geron. The rest of the authors have no financial conflicts of interest to disclose.The authors would like to acknowledge Jill Gregory for the creation of Fig. 1. The authors would like to acknowledge Michael Franklin, MS for assistance in editing the manuscript. J.D.B. is supported in part by Institutional Research Grant #129819-IRG-16-189-58-IRG-114 from the American Cancer Society, OT2 HL15275801 and American Heart Association Career Development Award. Funding Information: J.D.B. is supported in part by Institutional Research Grant # 129819-IRG-16-189-58-IRG-114 from the American Cancer Society , OT2 HL15275801 and American Heart Association Career Development Award. Funding Information: DT receives research clinical research funding from Astellas Pharma and consulting fees from AbbVie and CTI Biopharma. JDB receives research funding from Bayer independent of studies herein. RP receives consultancy fees from Sirtex Medical and is on the advisory boards of Medtronic, Blackswan Medical, and Scientia Inc. and is on the speakers' bureau of Medtronic. JM receives clinical research funding from Incyte , Janssen , CTI Biopharma , PharmaEssentia , Novartis , Roche , Kartos , Promedior Merck and consulting fees from Promedior, Prelude, Galecto, Incyte, Celgene, Kartos, and Geron. The rest of the authors have no financial conflicts of interest to disclose. Publisher Copyright: © 2022 Elsevier Ltd

PY - 2022/10

Y1 - 2022/10

N2 - Splanchnic vein thrombosis (SVT) in the setting of myeloproliferative neoplasm (MPN) is a unique clinical entity that requires close interdisciplinary coordination for proper diagnosis and management. The pathobiology of MPN-SVT is not fully understood, but recent developments have revealed the central role of endothelial cells. In this multidisciplinary review, we summarize the epidemiology of MPN-SVT and then critically evaluate the pathogenic features of this complication, with a focus on endothelial cell biology. We then discuss diagnostic considerations, including imaging modalities and MPN-specific investigations. Finally, we critically review the evidence supporting clinical management of MPN-SVT, including anticoagulation, interventional radiology procedures, MPN-related therapies, and liver transplantation. We conclude that further studies are needed to improve our understanding of MPN-SVT and the outcomes of patients with this debilitating complication.

AB - Splanchnic vein thrombosis (SVT) in the setting of myeloproliferative neoplasm (MPN) is a unique clinical entity that requires close interdisciplinary coordination for proper diagnosis and management. The pathobiology of MPN-SVT is not fully understood, but recent developments have revealed the central role of endothelial cells. In this multidisciplinary review, we summarize the epidemiology of MPN-SVT and then critically evaluate the pathogenic features of this complication, with a focus on endothelial cell biology. We then discuss diagnostic considerations, including imaging modalities and MPN-specific investigations. Finally, we critically review the evidence supporting clinical management of MPN-SVT, including anticoagulation, interventional radiology procedures, MPN-related therapies, and liver transplantation. We conclude that further studies are needed to improve our understanding of MPN-SVT and the outcomes of patients with this debilitating complication.

KW - Essential thrombocythemia

KW - Myelofibrosis

KW - Myeloproliferative

KW - Polycythemia vera

KW - Splanchnic vein

KW - Thrombosis

UR - http://www.scopus.com/inward/record.url?scp=85136714294&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85136714294&partnerID=8YFLogxK

U2 - 10.1016/j.thromres.2022.08.003

DO - 10.1016/j.thromres.2022.08.003

M3 - Review article

C2 - 35963121

AN - SCOPUS:85136714294

SN - 0049-3848

VL - 218

SP - 8

EP - 16

JO - Thrombosis Research

JF - Thrombosis Research

ER -

Splanchnic vein thrombosis associated with myeloproliferative neoplasms

Abstract

Bibliographical note

Keywords

PubMed: MeSH publication types

UN SDGs

Publisher link

Find It

Other files and links

Fingerprint

Cite this